GeNeuro SA (GNRO.PA)
EUR 0.08
(6.38%)
EUR 0.08
(6.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.73 Million EUR | 319.55% |
| 2022 | 1.84 Million EUR | 51.67% |
| 2021 | 1.21 Million EUR | -12.37% |
| 2020 | 1.38 Million EUR | -82.93% |
| 2019 | 8.12 Million EUR | 3590.24% |
| 2018 | 220.3 Thousand EUR | 20.98% |
| 2017 | 182.1 Thousand EUR | -0.65% |
| 2016 | 183.3 Thousand EUR | 4.03% |
| 2015 | 176.2 Thousand EUR | 4.01% |
| 2014 | 169.4 Thousand EUR | -45.51% |
| 2013 | 310.9 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 7.73 Million EUR | 319.55% |
| 2023 Q4 | 7.73 Million EUR | 0.0% |
| 2023 Q2 | 7.61 Million EUR | 0.0% |
| 2022 FY | 1.84 Million EUR | 51.67% |
| 2022 Q4 | 1.84 Million EUR | 0.0% |
| 2022 Q2 | 4.85 Million EUR | 0.0% |
| 2021 Q2 | 1.41 Million EUR | 0.0% |
| 2021 Q4 | 1.21 Million EUR | 0.0% |
| 2021 FY | 1.21 Million EUR | -12.37% |
| 2020 FY | 1.38 Million EUR | -82.93% |
| 2020 Q4 | 1.38 Million EUR | 0.0% |
| 2020 Q2 | 473 Thousand EUR | 0.0% |
| 2019 FY | 8.12 Million EUR | 3590.24% |
| 2019 Q2 | 768.3 Thousand EUR | 0.0% |
| 2019 Q4 | 8.12 Million EUR | 0.0% |
| 2018 Q2 | 33 Thousand EUR | 0.0% |
| 2018 FY | 220.3 Thousand EUR | 20.98% |
| 2018 Q4 | 220.3 Thousand EUR | 0.0% |
| 2017 Q2 | 215.3 Thousand EUR | 0.0% |
| 2017 FY | 182.1 Thousand EUR | -0.65% |
| 2017 Q4 | 182.1 Thousand EUR | 0.0% |
| 2016 FY | 183.3 Thousand EUR | 4.03% |
| 2016 Q4 | 183.3 Thousand EUR | 0.0% |
| 2016 Q2 | 7200.00 EUR | 0.0% |
| 2015 Q4 | 176.2 Thousand EUR | 0.0% |
| 2015 FY | 176.2 Thousand EUR | 4.01% |
| 2015 Q2 | 172.7 Thousand EUR | 0.0% |
| 2014 FY | 169.4 Thousand EUR | -45.51% |
| 2014 Q4 | 169.4 Thousand EUR | 0.0% |
| 2013 FY | 310.9 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -128.254% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 86.049% |
| Adocia SA | 13.08 Million EUR | 40.879% |
| Aelis Farma SA | 4.03 Million EUR | -91.625% |
| Biophytis S.A. | 8.27 Million EUR | 6.435% |
| Advicenne S.A. | 17.42 Million EUR | 55.594% |
| genOway Société anonyme | 7.23 Million EUR | -6.973% |
| IntegraGen SA | 1.12 Million EUR | -587.966% |
| Medesis Pharma S.A. | 1.2 Million EUR | -544.817% |
| Neovacs S.A. | 650 Thousand EUR | -1090.431% |
| NFL Biosciences SA | 62.17 Thousand EUR | -12345.395% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -77.615% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -184.809% |
| Sensorion SA | 2.86 Million EUR | -169.724% |
| Theranexus Société Anonyme | 3.64 Million EUR | -112.401% |
| TME Pharma N.V. | 1.16 Million EUR | -563.619% |
| Valbiotis SA | 6.87 Million EUR | -12.501% |
| TheraVet SA | 1.15 Million EUR | -567.128% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 14.005% |
| argenx SE | 18.1 Million EUR | 57.262% |
| BioSenic S.A. | 28.16 Million EUR | 72.523% |
| Celyad Oncology SA | 902 Thousand EUR | -757.849% |
| DBV Technologies S.A. | 13.01 Million USD | 40.564% |
| Galapagos NV | 9.59 Million EUR | 19.364% |
| Genfit S.A. | 70.17 Million EUR | 88.974% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -46.162% |
| Innate Pharma S.A. | 39.89 Million EUR | 80.604% |
| Inventiva S.A. | 37.4 Million EUR | 79.315% |
| MaaT Pharma SA | 14.07 Million EUR | 45.025% |
| MedinCell S.A. | 58.96 Million EUR | 86.876% |
| Nanobiotix S.A. | 50.56 Million EUR | 84.697% |
| Onward Medical N.V. | 16.87 Million EUR | 54.144% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 43.467% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 83.106% |
| Oxurion NV | 12.33 Million EUR | 37.264% |
| Pharming Group N.V. | 155.29 Million EUR | 95.017% |
| Poxel S.A. | 46.9 Million EUR | 83.501% |
| GenSight Biologics S.A. | 18.42 Million EUR | 58.011% |
| Transgene SA | 1.25 Million EUR | -515.577% |
| Financière de Tubize SA | 79.2 Million EUR | 90.23% |
| UCB SA | 3.03 Billion EUR | 99.745% |
| Valneva SE | 208.81 Million EUR | 96.294% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -20262.632% |